Highlights in Myelofibrosis Research at ASH 2024: Comparing Momelotinib, Other JAK Inhibitors

A discussion panel of myelofibrosis experts was convened at the 66th American Society of Hematology Annual Meeting & Exposition. The panel included Francesca Palandri, MD, PhD, of Università di Bologna, Andrew Kuykendall, MD, of Moffitt Cancer Center, and Lucia Masarova, MD, of MD Anderson Cancer Center, with Prithviraj Bose, MD, of MD Anderson Cancer Center as moderator.

In their continuing discussion, the panel members tell of their study work investigating momelotinib in relation to other Janus kinase (JAK) inhibitors in myelofibrosis. Among the subjects were momelotinib in the context of ruxolitinib-refractory disease, and the agent’s efficacy compared with pacritinib as measured by patient hemoglobin levels.